medication-rheumatoid-arthritis-upadacitinib-standard-dose-daily

Outcomes

01
mood-anxiety-hospital-anxiety-and-depression-scale-hads-anxiety-subscore-self-reported
1 evidence row
- silverberg_2024_rct_early-and-sustained-improvements-in-symptoms-and-quality-of-life-with-upadacitinib-in-adults-and-adolescents-with-moderate-to-severe-atopic-dermatitis-52-week-results-from-two-phase-iii-randomized-clinical-trials-measure-up-1-and-measure-up-2
02
mood-depression-hospital-anxiety-and-depression-scale-hads-depression-subscore-self-reported
1 evidence row
- silverberg_2024_rct_early-and-sustained-improvements-in-symptoms-and-quality-of-life-with-upadacitinib-in-adults-and-adolescents-with-moderate-to-severe-atopic-dermatitis-52-week-results-from-two-phase-iii-randomized-clinical-trials-measure-up-1-and-measure-up-2
03
qol-pgii-patient-global-impression-of-improvement-score-self-reported
1 evidence row
- silverberg_2024_rct_early-and-sustained-improvements-in-symptoms-and-quality-of-life-with-upadacitinib-in-adults-and-adolescents-with-moderate-to-severe-atopic-dermatitis-52-week-results-from-two-phase-iii-randomized-clinical-trials-measure-up-1-and-measure-up-2
04
qol-pgii-severity-change-rating-self-reported
1 evidence row
- silverberg_2024_rct_early-and-sustained-improvements-in-symptoms-and-quality-of-life-with-upadacitinib-in-adults-and-adolescents-with-moderate-to-severe-atopic-dermatitis-52-week-results-from-two-phase-iii-randomized-clinical-trials-measure-up-1-and-measure-up-2
05
qol-pgii-treatment-related-change-rating-self-reported
1 evidence row
- silverberg_2024_rct_early-and-sustained-improvements-in-symptoms-and-quality-of-life-with-upadacitinib-in-adults-and-adolescents-with-moderate-to-severe-atopic-dermatitis-52-week-results-from-two-phase-iii-randomized-clinical-trials-measure-up-1-and-measure-up-2
06
skin-atopic-dermatitis-impact-scale-adis-emotional-state-subscore-self-reported
1 evidence row
- silverberg_2024_rct_early-and-sustained-improvements-in-symptoms-and-quality-of-life-with-upadacitinib-in-adults-and-adolescents-with-moderate-to-severe-atopic-dermatitis-52-week-results-from-two-phase-iii-randomized-clinical-trials-measure-up-1-and-measure-up-2
07
skin-atopic-dermatitis-scoring-atopic-dermatitis-index-scorad-total-score-clinician-assessed-measured
1 evidence row
- silverberg_2024_rct_early-and-sustained-improvements-in-symptoms-and-quality-of-life-with-upadacitinib-in-adults-and-adolescents-with-moderate-to-severe-atopic-dermatitis-52-week-results-from-two-phase-iii-randomized-clinical-trials-measure-up-1-and-measure-up-2
08
skin-atopic-dermatitis-severity-scale-adss-total-score-self-reported
1 evidence row
- silverberg_2024_rct_early-and-sustained-improvements-in-symptoms-and-quality-of-life-with-upadacitinib-in-adults-and-adolescents-with-moderate-to-severe-atopic-dermatitis-52-week-results-from-two-phase-iii-randomized-clinical-trials-measure-up-1-and-measure-up-2
09
skin-dlqi-total-score-self-reported
1 evidence row
- silverberg_2024_rct_early-and-sustained-improvements-in-symptoms-and-quality-of-life-with-upadacitinib-in-adults-and-adolescents-with-moderate-to-severe-atopic-dermatitis-52-week-results-from-two-phase-iii-randomized-clinical-trials-measure-up-1-and-measure-up-2
10
skin-pain-severity-numeric-rating-scale-self-reported
1 evidence row
- silverberg_2024_rct_early-and-sustained-improvements-in-symptoms-and-quality-of-life-with-upadacitinib-in-adults-and-adolescents-with-moderate-to-severe-atopic-dermatitis-52-week-results-from-two-phase-iii-randomized-clinical-trials-measure-up-1-and-measure-up-2
11
skin-pruritus-urticaria-overall-management-scale-puoms-total-score-measured
1 evidence row
- silverberg_2024_rct_early-and-sustained-improvements-in-symptoms-and-quality-of-life-with-upadacitinib-in-adults-and-adolescents-with-moderate-to-severe-atopic-dermatitis-52-week-results-from-two-phase-iii-randomized-clinical-trials-measure-up-1-and-measure-up-2
12
skin-pruritus-worst-numeric-rating-scale-self-reported
1 evidence row
- silverberg_2024_rct_early-and-sustained-improvements-in-symptoms-and-quality-of-life-with-upadacitinib-in-adults-and-adolescents-with-moderate-to-severe-atopic-dermatitis-52-week-results-from-two-phase-iii-randomized-clinical-trials-measure-up-1-and-measure-up-2
13
sleep-quality-overall-perceived-rating-self-reported
1 evidence row
- silverberg_2024_rct_early-and-sustained-improvements-in-symptoms-and-quality-of-life-with-upadacitinib-in-adults-and-adolescents-with-moderate-to-severe-atopic-dermatitis-52-week-results-from-two-phase-iii-randomized-clinical-trials-measure-up-1-and-measure-up-2

medication-rheumatoid-arthritis-upadacitinib-standard-dose-daily

Outcomes

mood-anxiety-hospital-anxiety-and-depression-scale-hads-anxiety-subscore-self-reported

mood-depression-hospital-anxiety-and-depression-scale-hads-depression-subscore-self-reported

qol-pgii-patient-global-impression-of-improvement-score-self-reported

qol-pgii-severity-change-rating-self-reported

qol-pgii-treatment-related-change-rating-self-reported

skin-atopic-dermatitis-impact-scale-adis-emotional-state-subscore-self-reported

skin-atopic-dermatitis-scoring-atopic-dermatitis-index-scorad-total-score-clinician-assessed-measured

skin-atopic-dermatitis-severity-scale-adss-total-score-self-reported

skin-dlqi-total-score-self-reported

skin-pain-severity-numeric-rating-scale-self-reported

skin-pruritus-urticaria-overall-management-scale-puoms-total-score-measured

skin-pruritus-worst-numeric-rating-scale-self-reported

sleep-quality-overall-perceived-rating-self-reported